法国生物学家迪迪埃·拉乌尔特领导的团队应用氯喹治疗新冠病毒临床测试初见成效,24例临床测试显示,其中四分之三的患者治疗六日后病毒消失。

这是怎么回事?

CNN报道:

Study rules out coronavirus drug: A French study has found that hydroxychloroquine doesn't help coronavirus patients and was associated with heart complications. The drug, usually used to prevent and treat malaria, has been touted as a "game changer" by US President Donald Trump.
 
浏览附件893186浏览附件893187浏览附件893193浏览附件893194

浏览附件893193
浏览附件893194
浏览附件893186
浏览附件893187

COVID-19 Update 13: Randomized Controlled Trial of Hydroxychloroquine (Chen et al., Wuhan, China)
羟氯喹的随机对照试验(Chen等,中国武汉)
2月28日起,武汉人民?医院进行的一项随机临床试验,遵循了很好的科研原则。142名确诊病人,选样条件为,大于18岁,阳性,确诊患有肺炎,氧饱和度大于93%,都选取轻症患者,80名病人被排除,剩余62人分成两组,性别,年龄大体相当,一组每日400毫克羟氯喹,另外31为病人为对照组,进行其他方法治疗。病人和医生都不知道实情,每天测量3次体温,和检查咳嗽状况,第一天和第六天做CT检查。

使用羟氯喹组发烧,咳嗽的恢复时间短于对照组,分别为2天对3天,对照组有4人转为重症,羟氯喹组无人转重症,羟氯喹组有两人出现过敏反应:一人出疹子,一人头疼。CT检查发现,羟氯喹组81%有所改进,对照组为55%。

这是个好消息。我们期待听到有关最近启动的世界卫生组织大型试验的结果,该试验还评估了氯喹(以及其他药物)。

Finally, we have a randomized clinical trial assessing the efficacy of hydroxychloroquine for the treatment of mild cases of COVID-19. The trial was performed in Remnin Hospital in Wuhan and seems to have adhered to good scientific research principles. Also, their chosen outcomes (recovery times and CT findings) are much more relevant as compared to PCR of nasopharyngeal swabs. This is great news. We are looking forward to hearing about the results of the recently launched WHO mega-trial, which also assesses chloroquine (among other drugs).


中国武汉同济医院的科学家新发表的羟氯喹对比试验,结论:应为新冠病毒重症患者开处方HCQ,以挽救生命。

所有病人加同样的基础治疗羟氯喹组(48人)非羟氯喹组(502人)
死亡率18.8% (9/48人)47.4% (238/502)
死亡前存活时间15天8天
炎症细胞因子5.222.2


Sci China Life Sci

. 2020 May 15;1-7.
doi: 10.1007/s11427-020-1732-2. Online ahead of print.
Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19
Bo Yu 1, Chenze Li 1, Peng Chen 1, Ning Zhou 1, Luyun Wang 1, Jia Li 2, Hualiang Jiang 2 3, Dao-Wen Wang 4

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments. We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients. In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020. All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments. Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments. We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05). The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL-1 at the beginning of the treatment to 5.2 (3.0-23.4) pg mL-1 (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19.

 
已经被很多科学团队证明无效。

我要我侄子给我寄点。他说对新冠肺炎没用,对人有副作用。他是医生。
 
已经被很多科学团队证明无效。

我要我侄子给我寄点。他说对新冠肺炎没用,对人有副作用。他是医生。
我不知道为什么最近的研究结论是基本完全无效,唯有对心脏病有很大的风险。

可是武汉两家医院的对比试验表明是有明显疗效的。前一个人民医院的试验,只用于轻症患者,计量比较大:每天400毫克,后一个同济医院,用于重症患者,加其他必要的基础治疗,似乎计量相同:每天200毫克 x 2,效果显著。之前,法国,南韩,和中国都在用这个药加阿奇霉素或者锌一起,后来好像看到法国对这药的负评,南韩治愈率很高,这药应当是功不可没的。

不知到了美国,总统越吹,风险就变得越大了。真是奇了怪了。真怀疑美国医院使用不当。
 
我不知道为什么最近的研究结论是基本完全无效,唯有对心脏病有很大的风险。

可是武汉两家医院的对比试验表明是有明显疗效的。前一个人民医院的试验,只用于轻症患者,计量比较大:每天400毫克,后一个同济医院,用于重症患者,加其他必要的基础治疗,似乎计量相同:每天200毫克 x 2,效果显著。之前,法国,南韩,和中国都在用这个药加阿奇霉素或者锌一起,后来好像看到法国对这药的负评,南韩治愈率很高,这药应当是功不可没的。

不知到了美国,总统越吹,风险就变得越大了。真是奇了怪了。真怀疑美国医院使用不当。
不是特效药,接下来的事就很难判断了。
有的死了,有的活了,接下来就靠统计,统计要求基数大,前提条件一致,包括基础病,年龄,性别,感染时间,开始用药时间,用药剂量,这些要求都可能是做不到的。而且,在治疗过程中,看着病人不行了,总得想其它办法吧,这么一搞,谁知道是哪个的效果啊。
这种东西最后往往都靠一张嘴,说有效就有效,说无效就无效。
所以啊,我说,如果不是特效药,就干脆当无效东西。实在没招了就用吧。
 
不是特效药,接下来的事就很难判断了。
有的死了,有的活了,接下来就靠统计,统计要求基数大,前提条件一致,包括基础病,年龄,性别,感染时间,开始用药时间,用药剂量,这些要求都可能是做不到的。而且,在治疗过程中,看着病人不行了,总得想其它办法吧,这么一搞,谁知道是哪个的效果啊。
这种东西最后往往都靠一张嘴,说有效就有效,说无效就无效。
所以啊,我说,如果不是特效药,就干脆当无效东西。实在没招了就用吧。
假设中国的这两组对照试验是认真的,这药还是有疗效的,剩下的就是副作用的问题了,几天之内不超过800毫克的计量,不应当有那么严重的副作用。只要不使病情加重,把人治死,有点疗效就不错了。
 
看来cfc搜索功能修复了。
 
中国武汉同济医院的科学家新发表的羟氯喹对比试验,结论:应为新冠病毒重症患者开处方HCQ,以挽救生命。

所有病人加同样的基础治疗羟氯喹组(48人)非羟氯喹组(502人)
死亡率18.8% (9/48人)47.4% (238/502)
死亡前存活时间15天8天
炎症细胞因子5.222.2


Sci China Life Sci

. 2020 May 15;1-7.
doi: 10.1007/s11427-020-1732-2. Online ahead of print.
Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19
Bo Yu 1, Chenze Li 1, Peng Chen 1, Ning Zhou 1, Luyun Wang 1, Jia Li 2, Hualiang Jiang 2 3, Dao-Wen Wang 4

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments. We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients. In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020. All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments. Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments. We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05). The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL-1 at the beginning of the treatment to 5.2 (3.0-23.4) pg mL-1 (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19.

这么古老的贴又顶上来了,很好。

我很早就报道过中国武汉同济医院去年2月开始就进行过氯喹的对比试验,结果是有些效果的。可惜后来各国越来越多的实践证明似乎效果不够理想。
 
后退
顶部